belinostat   Click here for help

GtoPdb Ligand ID: 7496

Synonyms: Beleodaq® | PXD-101 | PXD101
Approved drug PDB Ligand
belinostat is an approved drug (FDA (2014))
Compound class: Synthetic organic
Comment: Belinostat is a pan-histone deacetylase (HDAC) inhibitor [1,3].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: belinostat

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 3
Rotatable bonds 6
Topological polar surface area 103.88
Molecular weight 318.07
XLogP 1.95
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES ONC(=O)C=Cc1cccc(c1)S(=O)(=O)Nc1ccccc1
Isomeric SMILES ONC(=O)/C=C/c1cccc(c1)S(=O)(=O)Nc1ccccc1
InChI InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+
InChI Key NCNRHFGMJRPRSK-MDZDMXLPSA-N
No information available.
Summary of Clinical Use Click here for help
Belinostat was approved by the US FDA in 2014 for the treatment of patients with relapsed or refactory peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL). In the EU, belinostat has orphan designation to treat peripheral T-cell lymphoma (nodal, other extranodal and leukaemic / disseminated) and malignant thymoma.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Belinostat is a hydroxamate-type HDAC inhibitor which induces apoptosis in vitro [2,4-6] thereby reducing tumour load. HDACs function as integral components of multi-protein complexes which are recruited to specific regions of the genome. These protein complexes control the expression and silencing (repression) of specific sets of genes which provides the basis for the reported phenotypes typical of malignant cancer cells. HDAC inhibition causes transcriptional de-repression of genes modulating growth inhibition, differentiation and apoptosis of cancer cells.
External links Click here for help
For extended ADME data see the following:

Drugs.com
European Medicines Agency (EMA)